Flow Cytometry Evaluated for Cord Blood Differentials
|
By LabMedica International staff writers Posted on 20 Feb 2013 |
The potential of flow cytometry to analyze and to report leukocyte differentials on cord blood to be used for hematopoietic stem cells has been evaluated.
Currently, the reference method for white blood cell (WBC) is the microscopic manual count, but international standards advise that potential donor blood is tested for total nucleated cell count, nucleated red blood cell count (nRBCs), total number of CD34 cells, viability or potency as measured by viable CD34 cells. Colony-forming unit assays, microbial cultures, and finally a complete blood count with WBC differential are also advisable.
Hematologists at the Centre Hospitalier Universitaire (CHU; Rennes, France) analyzed 161 cord bloods between November 2010 and February 2011. WBC differentials were determined for each sample, by a cell counter, a manual method, and the flow cytometry using an antibody cocktail. WBC differential includes the count of neutrophils, eosinophils, basophils, lymphocytes, monocytes, immature granulocytes, and blasts cells.
All samples were analyzed on the HematoFlow platform (Beckman Coulter, Miami, FL, USA) within 12 hours of collection. This platform is built around Beckman Coulter's FP1000 cell preparator, along with their FC500 five-color flow cytometer. The antibody cocktail used was another Beckman Coulter product called the CytoDiff.
A good correlation was obtained for neutrophils, lymphocytes, and immature granulocytes when the manual method was compared to the flow cytometry, but was weaker for eosinophils and even lower for monocytes and basophils. The flow cytometry method employed allowed the identification of 12 cell
subtypes (neutrophils, eosinophils, basophils, B lymphocytes, T-non-cytotoxic and T cytotoxic/Natural Killer (NK) lymphocytes, CD16 negative monocytes and CD16 positive monocytes, immature granulocytes, B blasts, T blasts and non-B-non-T blasts) within a single panel of antibodies and a minimal volume of 50 µL of blood.
The authors concluded that the flow differential has some drawbacks such as the cost of CytoDiff reagent, but this can be balanced by the reduction in technician time required for manual counting and the use of a standardized product. The flow cytometry appears as a technique completely adapted to provide a WBC differential on a cord blood sample. The additional cell subset counts offered in the same turn-around-time would probably be exploited in the near future to better characterize the engraftment potential. The study was published in the February 2013 issue of the International Journal of Laboratory Hematology.
Related Links:
Centre Hospitalier Universitaire
Beckman Coulter
Currently, the reference method for white blood cell (WBC) is the microscopic manual count, but international standards advise that potential donor blood is tested for total nucleated cell count, nucleated red blood cell count (nRBCs), total number of CD34 cells, viability or potency as measured by viable CD34 cells. Colony-forming unit assays, microbial cultures, and finally a complete blood count with WBC differential are also advisable.
Hematologists at the Centre Hospitalier Universitaire (CHU; Rennes, France) analyzed 161 cord bloods between November 2010 and February 2011. WBC differentials were determined for each sample, by a cell counter, a manual method, and the flow cytometry using an antibody cocktail. WBC differential includes the count of neutrophils, eosinophils, basophils, lymphocytes, monocytes, immature granulocytes, and blasts cells.
All samples were analyzed on the HematoFlow platform (Beckman Coulter, Miami, FL, USA) within 12 hours of collection. This platform is built around Beckman Coulter's FP1000 cell preparator, along with their FC500 five-color flow cytometer. The antibody cocktail used was another Beckman Coulter product called the CytoDiff.
A good correlation was obtained for neutrophils, lymphocytes, and immature granulocytes when the manual method was compared to the flow cytometry, but was weaker for eosinophils and even lower for monocytes and basophils. The flow cytometry method employed allowed the identification of 12 cell
subtypes (neutrophils, eosinophils, basophils, B lymphocytes, T-non-cytotoxic and T cytotoxic/Natural Killer (NK) lymphocytes, CD16 negative monocytes and CD16 positive monocytes, immature granulocytes, B blasts, T blasts and non-B-non-T blasts) within a single panel of antibodies and a minimal volume of 50 µL of blood.
The authors concluded that the flow differential has some drawbacks such as the cost of CytoDiff reagent, but this can be balanced by the reduction in technician time required for manual counting and the use of a standardized product. The flow cytometry appears as a technique completely adapted to provide a WBC differential on a cord blood sample. The additional cell subset counts offered in the same turn-around-time would probably be exploited in the near future to better characterize the engraftment potential. The study was published in the February 2013 issue of the International Journal of Laboratory Hematology.
Related Links:
Centre Hospitalier Universitaire
Beckman Coulter
Latest Hematology News
- New Guidelines Aim to Improve AL Amyloidosis Diagnosis
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







